| Before liraglutide | After liraglutide | Before placebo | After placebo | N | Treatment effect | Difference (95 % CI) | p value | |
---|---|---|---|---|---|---|---|---|---|
Baseline | 12Â weeks | Baseline | 12Â weeks | Liraglutide | Placebo | ||||
LVEF, % | |||||||||
 Rest | 59.46 (7.44) | 60.13 (9.07) | 59.27 (7.92) | 59.41 (7.92) | 30 | 0.67 (6.30) | 0.13 (4.95) | 0.54 (−2.38 to 3.45) | 0.710 |
 Low stress | 70.73 (9.58) | 71.03 (10.7) | 71.31 (9.51) | 71.44 (8.43) | 29 | 0.28 (6.27) | 0.25 (6.56) | 0.03 (−3.25 to 3.32) | 0.984 |
 Peak stress | 75.72 (9.52) | 76.92 (9.14) | 76.26 (8.72) | 76.02 (8.12) | 24 | 0.87 (6.91) | −0.25 (7.26) | 1.12 (−3.45 to 5.69) | 0.618 |
 Recovery | 60.65 (10.38) | 64.91 (10.44) | 62.52 (10.20) | 62.84 (9.88) | 29 | 4.25 (7.13) | 0.20 (8.97) | 4.06 (−0.81 to 8.93) | 0.099 |
WMSI | |||||||||
 Rest | 1.088 (0.155) | 1.084 (0.163) | 1.088 (0.144) | 1.075 (0.140) | 30 | −0.003 (0.065) | −0.013 (0.055) | 0.009 (−0.018 to 0.037) | 0.492 |
 Low stress | 1.078 (0.202) | 1.077 (0.171) | 1.059 (0.143) | 1.048 (0.128) | 29 | 0.004 (0.097) | −0.011 (0.056) | 0.007 (−0.035 to 0.049) | 0.725 |
 Peak stress | 1.079 (0.235) | 1.052 (0.160) | 1.058 (0.149) | 1.060 (0.213) | 24 | −0.03 (0.10) | 0.01 (0.08) | −0.038 (−0.112 to 0.035) | 0.292 |
 Recovery | 1.090 (0.198) | 1.096 (0.212) | 1.081 (0.157) | 1.090 (0.192) | 29 | 0.007 (0.07) | 0.006 (0.11) | 0.001 (−0.045 to 0.047) | 0.963 |
GLS | |||||||||
 Rest | 16.26 (2.60) | 15.53 (2.72) | 16.44 (3.07) | 16.34 (2.90) | 30 | −0.73 (1.87) | −0.10 (1.87) | −0.63 (−0.42 to 1.67) | 0.231 |
GLSR, s−1 | |||||||||
 Rest | 0.90 (0.18) | 0.91 (0.18) | 0.86 (0.17) | 0.88 (0.2)18 | 30 | 0.01 (0.15) | 0.02 (0.14) | −0.01 (−0.05 to 0.08) | 0.713 |